

Aaron Broadwell, MD
President

March 19, 2025

Gary Feldman, MD
Immediate Past President

Assembly Appropriations
State House Annex
Committee Room 11, 4th Floor
Trenton, NJ 08608

Madelaine Feldman, MD
VP, Advocacy & Government Affairs

Michael Saitta, MD, MBA
Treasurer

Re: Support A 5217 – Ban Copay Accumulator Adjustment Programs, Maximizer Programs and Alternative Funding Programs

Firas Kassab, MD
Secretary

Erin Arnold, MD
Director

Chair Swain, Vice Chair Reynolds-Jackson and members of the Assembly Appropriations Committee:

Leyka Barbosa, MD
Director

The Coalition of State Rheumatology Organizations (CSRO) supports A 5217, which would require health plans to count third-party discounts and payments made on behalf of patients towards the patient's copayments, coinsurance, deductibles, or other out-of-pocket costs. It would also ban the use of alternative funding programs and maximizer programs for prescription drugs. CSRO serves the practicing rheumatologist and is comprised of over 40 state rheumatology societies nationwide with a mission of advocating for excellence in the field of rheumatology and ensuring access to the highest quality of care for the management of rheumatologic and musculoskeletal disease.

Kostas Botsoglou, MD
Director

Mark Box, MD
Director

Michael Brooks, MD
Director

Amish Dave, MD, MPH
Director

Rheumatologic diseases, such as rheumatoid arthritis, psoriatic arthritis and lupus, are systemic and incurable, but innovations in medicine over the last several decades have enabled rheumatologists to better manage these conditions. With access to the right treatment early in the disease, patients can generally delay or even avoid damage to their bones and joints, as well as reduce reliance on pain medications and other ancillary services, thus improving their quality of life.

Harry Gewanter, MD, MACR
Director

Adrienne Hollander, MD
Director

Robert Levin, MD
Director

Copay Accumulator Adjustment Programs

Amar Majjhoo, MD
Director

Many rheumatologic patients are prescribed specialty drugs for chronic conditions after trying and failing all available lower cost alternatives and are often prescribed multiple medications for several conditions. These specialty medications can be very expensive, and many patients would go without treatment if they did not have access to copay assistance. Copay assistance may be provided to the patient through "copay cards", furnished by manufacturers to help cover a patient's cost sharing as well as through non-profit foundations, which offer monetary assistance to patients.

Gregory Niemer, MD
Director

Joshua Stollow, MD
Director

Until recently, health plans would count the value of the card towards the patient's deductible. However, health insurers and pharmacy benefit managers now regularly use programs known as "copay accumulator adjustment programs." In New Jersey, almost 17% of individual health plans reviewed in 2025 include a copay accumulator adjustment program.¹ These programs allow the patient to continue using their copay card but do **not** allow the copay assistance to count towards the patient's deductible or maximum out-of-pocket limit, driving great patient out-of-pocket costs. Unfortunately, these copay accumulator adjustment programs impact patients living with chronic conditions who require high-cost specialty medications, including rheumatic diseases, as well as patients who can only afford high deductible health plans.

EXECUTIVE OFFICE

Leslie Del Ponte
Executive Director

Through these accumulator programs, insurers pocket the value of the copay assistance, in addition to demanding the full deductible value from the patient. Many copay cards hit an annual limit, at which point the patient is often responsible for the full copay for their medication if they have not met their plan's deductible or maximum out-of-pocket limit. Some patients may have cost sharing responsibilities of \$5,000 a month or higher for their specialty medications or to cover multiple medications to treat their chronic conditions. When faced with these high out-of-pocket costs, many patients may abandon their treatment plan, forcing stable patients to discontinue their treatments. This can result in disease progression, flare ups, increased steroid use, and even loss of effectiveness of their original therapy if eventually restarted. Managing the results from non-adherence to their medication requires the use of substantially more resources than allowing for continuity of care from the start.ⁱⁱ

It is important to note that the Federal Employer Health Benefits prohibits the use of copay accumulator programs, according to a January 2024 letter. In this letter by the Federal Office of Personnel Management, the Office explicitly states that it will, “decline any arrangements which may manipulate the prescription drug benefit design or incorporate any programs such as copay maximizers, copay optimizers, or other similar programs as these types of benefit designs **are not in the best interest of enrollees or the Government.**”ⁱⁱⁱ We encourage the legislature to take a similar position on behalf of patients throughout New Jersey.

Maximizers Increase Patient Out-of-Pocket Costs

This legislation would also ban the use of copay maximizer programs, which were developed for the health plan and PBM to “maximize” and capture the full value amount of the manufacturer copay card. These programs have become all too common, with 47% of covered lives across the country enrolled in plans with a maximizer.^{iv} Through these programs, patients essentially surrender their copay cards to the maximizer program. The health plan or PBM then adjusts the patient's cost sharing to equal the card value. At times, the PBM may collect beyond the patient's original cost sharing responsibility if they are able to drain the full value of the card from the manufacturer through these maximizer programs. These programs are harmful to patients because the amounts collected by the maximizer do not count toward the patient's deductible or maximum out-of-pocket limit. Thus, they require patients to pay out-of-pocket longer and can make it difficult for patients to afford their medications.

Alternative Funding Programs

This legislation would also prohibit the use of alternative funding programs (AFPs), which are run by third-party vendors and utilized by health plans for *specialty* medications. Specialty medications are commonly more expensive as they are used to treat rare, complex and/or chronic conditions, including many rheumatologic diseases. They are usually placed in the highest tier of the prescription drug formulary. These programs profit off patient assistance programs and non-profit foundation funding that is intended as a safety net for truly uninsured patients, simultaneously delaying patient access to essential prescription medications.

The AFP works with the health plan to carve out specialty drugs from the plan's coverage and claims that specialty medications are non-essential health benefits (EHBs). This can allow the patient to appear uninsured, making the patient eligible to obtain their medication through an alternative source, including non-profit foundations, manufacturer patient assistance programs or international importation. If the AFP is unable to secure the medication from an alternative source, the health plan can choose to cover the medication as a normal pharmacy benefit, making the entire process for naught. In other cases, the health plan may still choose not to cover the medication, and the insured patient is required to pay out-of-pocket for the full cost of the drug.

AFPs Delay Patient Access to Essential Medications

Patients are often compelled to sign up for an AFP or else they are forced to pay the full price of the drug out-of-pocket. Once the patient enrolls in the AFP, there is often a significant delay in obtaining the medication as the AFP works to secure their medication from an alternative source. At times that alternative source may be a pharmacy outside of the United States, which means the drug is not subject to the same integrity standards as U.S. medications. It is important to note that in 2023, the FDA stated that it would take action against any AFPs that “import or offer [to] import illegal products.”^v

Patients that suffer from complex chronic conditions, such as rheumatoid arthritis and other rheumatologic diseases, require continuity of care to successfully manage their condition. Any disease progression caused by a delay or complete loss of access to an appropriate treatment can be irreversible, life threatening, and cause the patient’s original treatment to lose effectiveness. AFPs work to game the system at the expense of the patient’s health and maintenance of their health condition.

AFPs Exacerbate Patient Out-of-Pocket Costs

CSRO is particularly concerned about how AFPs impact patients with rheumatic conditions, such as rheumatoid arthritis, lupus and psoriatic arthritis, as well as other inflammatory conditions, such as multiple sclerosis and inflammatory bowel disease. These patients often require complex, and thus more expensive, medications. Since the medication is classified as a non-EHB, any outside assistance secured by the AFP does not count towards the patient’s cost sharing responsibility. This exacerbates patient out-of-pocket costs, as the assistance does not count towards the patient’s cost sharing.

Rheumatologists are entrusted with the safe care of patients with rheumatoid arthritis and other autoimmune diseases that require the careful choice of safe and effective medications and biological therapies. Copay accumulator adjustment programs, maximizer programs and alternative funding programs are all harmful to patients and drive patient out-of-pocket costs. As the legislature continues to consider opportunities to address the cost of medications for patients throughout New Jersey, we encourage you protect patients and support A 5217. We thank you for your consideration and are happy to further detail our comments to the Committee upon request.

Respectfully,



Adrienne Hollander, MD, FACR
Member At Large
New Jersey Rheumatology Association
www.njrheumatology.org



Madelaine A. Feldman, MD, FACR
VP, Advocacy & Government Affairs
Coalition of State Rheumatology Organizations
www.CSRO.info

ⁱ The Aids Institute. “[Our Loss, Their Gain: Copay Accumulator Adjustment Policies in 2025](#).” February 2025.

ⁱⁱ Rheumatol Ther. “[The Economic Benefit of Remission for Patients with Rheumatoid Arthritis](#).” October 2022.

ⁱⁱⁱ U.S. Office of Personnel Management Healthcare and Insurance. “[Pharmacy Benefits Management \(PBM\) Transparency Standards](#).” January 2024.

^{iv} Drug Channels. “[Why Plan Sponsors and PBMs Are Still Falling Hard for Copay Maximizers](#).” February 2025.

^v U.S. Food & Drug Administration. [Letter to the Aired Alliance](#). April 2023.